Every 8-K that Faeth Therapeutics, Inc. (FTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTH filings page.
Faeth Therapeutics, Inc. (FTH) reports that its Board of Directors increased in size from five to six members and appointed co‑founder and cancer biologist Karen Vousden, Ph.D. as a Class II director, effective September 11, 2026. Her term runs until the 2029 annual meeting of stockholders, and she was also named to the Board’s Compensation Committee. In connection with her appointment, Dr. Vousden will receive standard non‑employee director cash compensation and an initial equity award under the 2026 Equity Incentive Plan consisting of an option to purchase 25,000 shares of common stock at the closing market price on the grant date, vesting in equal monthly installments over three years and fully vesting upon a Change in Control, subject to continued service.
Faeth Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026 and provided clinical and corporate updates. The company highlighted its combination with Sensei Biotherapeutics and a concurrent $200 million PIPE financing, which it says provides capital to advance its multi-node inhibitor PIKTOR across multiple cancers.
For the quarter, total operating expenses were $18,385 (in thousands), up from $5,206 (in thousands) a year earlier, driven by research and development of $9,180 (in thousands) and general and administrative expenses of $9,205 (in thousands). Net loss was $16,007 (in thousands), compared with $4,936 (in thousands), or $2.84 net loss per share versus $3.91. Cash and cash equivalents were $26,903 (in thousands) and marketable securities were $159,538 (in thousands) as of June 30, 2026.
Operationally, Faeth reported that topline results from its Phase 2 PIK-201 trial in advanced endometrial cancer are on track for year-end 2026, and that the first patient was dosed in its Phase 1b/2 PIK-101 trial in HR+ breast cancer in April 2026, with initial data anticipated in 2027.
Faeth Therapeutics, Inc. approved one-time supplemental performance-based stock option grants under its 2026 Equity Incentive Plan for employees who were employed as of February 19, 2026, including key executives.
The Chief Executive Officer received options for 398,018 shares, the General Counsel 84,766 shares and the Senior Vice President, Finance 30,824 shares. Each option has an exercise price equal to the closing price of the common stock on the grant date and vests in a single tranche only after a Stock Price Hurdle of $70.00 per share is achieved during a Performance Period that ends on the fourth anniversary of the grant date and at least one year has elapsed, subject to continued service. Unvested options are forfeited if the hurdle is not met or service ends, while a qualifying change in control with per-share consideration of at least $70.00 accelerates vesting.